HIV and Hepatitis C in Cameroon: What You Need to Know
"A new study reveals the concerning rates of HIV/HCV co-infection and highlights the importance of screening and awareness."
HIV and Hepatitis C (HCV) co-infection is a growing global health concern, increasing the risk of liver disease and other complications for those affected. Sub-Saharan Africa faces significant challenges in addressing this issue due to limited awareness and resources.
While advancements in antiretroviral therapy have greatly improved the lives of people living with HIV, co-infection with HCV can undermine these benefits. Unlike HIV, management plan for HCV infection is still in progress, without any written plan available to date. Early detection and treatment of HCV are crucial, but screening programs are not yet as widespread as HIV testing, even in major hospitals.
A recent study in Cameroon investigated the prevalence of HIV/HCV co-infection and its impact on liver health. By examining patient data and conducting screenings, the researchers aimed to provide valuable insights for improving healthcare strategies in the region. This research highlights the urgent need for increased awareness, screening, and integrated care for individuals at risk of HIV/HCV co-infection.
Cameroon’s Current HIV Picture
The CDC reports that U.S.-supported partners have helped Cameroon’s Ministry of Health deliver clinical services in more than 340 health facilities across all ten regions. The CAMPHIA 2024–2025 survey provided an updated national picture of the HIV epidemic, with findings presented in Yaoundé on July 7, 2026. UNAIDS tracks Cameroon’s new HIV infections, AIDS-related deaths, and coverage of antiretroviral therapy, while a hospital-based study examined HIV/HCV coinfection alongside liver markers and CD4 counts.
A Cautious, Integrated Approach
Assessment and care for HIV and hepatitis C generally require coordinated testing, clinical evaluation, and follow-up rather than treating either infection in isolation. However, the available material for this subsection does not establish a single standardized approach for Cameroon or quantify its limitations. Practices and outcomes may vary across settings, so readers should interpret broad recommendations cautiously and seek guidance from qualified health professionals.
Early Coinfection Evidence
A population-based cross-sectional survey conducted in September 2001 examined HIV/HCV coinfection in three villages in Cameroon’s East Province, about 250 kilometers from Yaoundé. The 2007 reports described HCV seroprevalence in Cameroon as 13.8%, among the highest levels reported worldwide, while also noting that population-level coinfection data were limited. The same historical literature identified improved treatment strategies and management guidelines for coinfection as an important future goal.
Key Findings: Understanding HIV/HCV Co-infection in Cameroon
The study, conducted across three hospital settings in Yaoundé, Cameroon, involved screening both newly diagnosed HIV patients and individuals attending the hospitals for other reasons. Researchers analyzed blood samples for HCV antibodies and antigens, as well as markers of liver function and CD4 cell counts. The findings revealed several important trends:
- Gender Disparities: Women comprised the majority (72%) of people with HIV, while men were more affected by HCV (78.57%).
- Age as a Factor: The average age of co-infected individuals was higher, with 93.33% being 50 years or older. This suggests age as a potential risk factor for HIV/HCV co-infection.
- Impact on Liver Health: The study found correlations between CD4 cell counts and liver function markers, indicating that HIV/HCV co-infection can accelerate liver damage.
New Studies in Cameroon
A May 2026 study assessed HCV seroprevalence, comorbidities, liver-enzyme abnormalities, and possible risk factors among HIV-infected adults attending Bamenda Regional Hospital in the North West Region, where the authors reported that data remain limited. Another study examined HIV/HCV coinfection through viral seroprevalence and its relationship with liver markers and CD4 counts in three Cameroonian hospitals. Recent discussion of rural Cameroon has likewise focused on the prevalence and risk factors of HIV/HCV coinfection in population studies.
Evidence Gaps and Uncertainty
The available material suggests that conclusions about HIV/HCV coinfection in Cameroon should be interpreted cautiously because evidence is drawn from particular hospitals, regions, or rural populations. Limited data can make it difficult to generalize findings nationally or compare risk factors consistently. This does not invalidate the studies, but it means that prevalence estimates and explanations may remain uncertain without broader, standardized surveillance.
Comparing Local Evidence
The supplied material does not provide a matched comparison of HIV and hepatitis C outcomes across Cameroon’s regions or against other countries. It does indicate that studies have examined different settings, including Bamenda Regional Hospital, rural communities, and three hospitals. Comparisons should therefore account for differences in population, location, and study design rather than treating all findings as directly equivalent.
The Path Forward: Improving HIV/HCV Care in Cameroon
The study's findings call for immediate action to integrate HCV screening into existing HIV care programs in Cameroon. By making HCV testing compulsory for patients and incorporating it into national guidelines, healthcare providers can identify and treat co-infected individuals more effectively.
Toward Better Coinfection Care
Research from Cameroon indicates that HBV or HCV coinfection was relatively common among HIV-infected participants in Kumba Health District, and that response to HAART differed between monoinfected and coinfected participants when weight, CD4 count, and viral load were considered. The same evidence notes that national HBV and HCV prevalence data remain inconclusive. A 2025 study examining 11 HIV clinics in Cameroon’s Centre Region focused on integrating HCV testing and treatment into routine HIV care and measuring treatment cure rates.
Tracking Regional HIV Trends
A 2025 Frontiers analysis examined differences in HIV infection trends from 2012 to 2022 across remote communities in two administrative regions of Cameroon’s equatorial rainforest. The study places these regional trends within Cameroon’s longer history of HIV-1M circulation since the beginning of the global HIV-1M pandemic. Future work will need to clarify how HIV patterns differ between remote communities and other settings, using geographically specific evidence.
Blood Safety and Coinfection Risk
A 2026 analysis of transfusion-related epidemiology and safety challenges reported that the pathogens it examined could occur as coinfections at a pooled proportion of 1.5%. Within the reported coinfection findings, HBV plus HCV was the most prevalent combination at 3.4%. The analysis also found that risks for HIV and Treponema pallidum infection were consistently higher among family donors.
Living With Uncertainty
People affected by HIV or hepatitis C may face uncertainty when evidence is limited or differs across regions and healthcare settings. Hospital-based and rural studies can identify important concerns, but their findings may not describe every person or community in Cameroon. Clear communication, appropriate testing, and access to qualified clinical care are therefore important, while individual decisions should be based on professional medical advice.
Increased awareness campaigns are also essential to educate the public about the risks of HIV/HCV co-infection and encourage individuals to get tested. These campaigns should target both men and women, as well as older adults who may be at higher risk.
Ultimately, a comprehensive approach that combines widespread screening, public education, and integrated care is needed to combat the growing threat of HIV/HCV co-infection in Cameroon and improve the health and well-being of its population.